Given the known RAS signalling crosstalks and adaptive feedback loops [9], horizontal dual inhibition of MEK and PI3 K pathways has been trialled extensively with no anti-tumour activity observed, in part due to poor pharmacodynamic (PD) effects and high toxicity [10–14]. Here, MAP2K7 is linked to neoplasm.